Strategic solutions for the early stages of drug development. We offer customised solutions selected from a existing global library of APIs, along with unique combinations from our exclusive range of APIs and excipients.

Evidence-based reports will be provided to our partner as early as the discovery phase. These would include an analytical report with comparative analyses of the TOP global drugs/APIs and the current R&D development Market. These reports evaluate key criteria such as dosage forms, efficacy, safety, patent purity and protection, and time to market.

For the first time in the world, disease-specific targeted APIs have been developed with production scaled to meet pharmaceutical process requirements. Cyclolab’s approach ensures effective formulations, right through the registration stage.

Your collaboration with us includes the preparation of the CTA application for regulatory approval in all phases of clinical trials, this is done with the involvement of the customer and the CRO.

Cyclolab, as the owner of the pharmaceutical technology, fully supports the CRO in this process.

All clinical trial phases are managed by the CRO with the involvement of specialists and the owner(s) of the pharmaceutical technology, therapeutic techniques, and results.

A - Compilation of safety, efficacy and optimal dosages, and design of trials are based on exclusive clinical practices.

B - Statistical bioanalytical analyses are conducted, with a focus on plasma bioanalytics where API components are measured at nanogram/mL levels.

Cyclolab's support ensures a successful trial outcome and guarantees reliable results.

The development and preparation of formulations and drugs for all phases of clinical trials are in accordance with the relevant pharmaceutical guidelines (GxP) - it is, however, advisable to use Cyclolab's facilities with injectable and non-injectable application forms, in order to shorten the timeframe.

Technology transfer takes place in parallel with clinical trials, and can be completed by the end of phase 3.

Services include scaling-up, process validation, quality control, drug release, and other compliance measures, ensuring the final product meets manufacturing standards.

Commercialization phase - for more than 50 years our company has been consistently specializing in scientific and laboratory development, including the industrial production of new generation APIs offering exclusivity to our customers. We also offer analytics of existing TOP-APIs on the market and their combination in formulation improvement, R&D - consulting.

While Cyclolab does not directly handle drug commercialization, we offer strategic-analytical services, including market forecasts and global API potential analysis.